The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Larotrectinib and Entrectinib for NTRK Fusion Tumors: Tissue-Agnostic Targeted Therapy

Pan-tumor therapy for rare but actionable NTRK gene fusions across diverse adult and pediatric malignancies

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Larotrectinib and Entrectinib for NTRK Fusion Tumors: Tissue-Agnostic Targeted Therapy?

NTRK genes encode tropomyosin receptor kinases TRKA, TRKB and TRKC normally involved in neuronal development and function.

Oncogenic NTRK fusions create constitutively active chimeric proteins driving tumor growth across diverse tissue types.

Larotrectinib is highly selective TRK inhibitor with broad tumor activity and excellent CNS penetration.

Entrectinib has broader kinase profile inhibiting TRK, ROS1 and ALK with CNS activity for brain metastases.

Tissue-agnostic FDA approval reflects biomarker-defined treatment paradigm transcending traditional histology-based therapeutic decisions.

Symptoms

Treatment-emergent neurological symptoms including dizziness, paresthesias and gait disturbance reflect TRK inhibition affecting normal neurological function.
Fatigue, weight changes, gastrointestinal symptoms and hepatotoxicity occur with monitoring required.
Bone fracture risk increases with longer treatment duration reflecting role of TRK signaling in bone homeostasis.
Withdrawal symptoms upon treatment discontinuation including pain, hyperalgesia and behavioral changes recognized phenomenon.
Pediatric patients require special monitoring with growth, developmental assessment and bone health surveillance.

Risk Factors

NTRK fusion testing requires comprehensive molecular testing using next-generation sequencing, RNA fusion panels or pan-TRK immunohistochemistry screening.
Rare tumors including infantile fibrosarcoma and secretory carcinoma show high NTRK fusion frequency justifying targeted testing.
Common cancers including thyroid, lung, colorectal and brain tumors harbor NTRK fusions in less than 1% requiring broad testing approaches.
Acquired resistance through secondary kinase domain mutations including solvent-front, gatekeeper and xDFG motif mutations affects long-term efficacy.
Pediatric considerations include weight-based dosing, growth monitoring and developmental assessment during therapy.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Treatment-resistant solid tumors particularly with rare histology should undergo comprehensive molecular profiling including NTRK fusion testing.
  • Pediatric solid tumors and infantile fibrosarcoma warrant NTRK testing given high yield and excellent treatment response.
  • Adult cancers with characteristic features including secretory breast carcinoma or papillary thyroid cancer specific subtypes warrant testing.
  • Severe neurological symptoms during treatment require evaluation balancing dose modification against treatment efficacy.
  • Fall and fracture risk requires bone health assessment, vitamin D, calcium supplementation and appropriate physical therapy.

Treatment Methods

01
Larotrectinib 100 mg twice daily for adults or weight-based dosing for pediatric patients represents standard regimen.
02
Entrectinib 600 mg once daily provides alternative with potential ROS1 and ALK activity for relevant indications.
03
Comprehensive monitoring including liver function, electrolytes, neurological examination and bone health assessment supports safety.
04
Acquired resistance management through next-generation TRK inhibitors including selitrectinib and repotrectinib for kinase domain mutations.
05
Multidisciplinary care including pediatric oncology when relevant, supportive care, rehabilitation services and patient registries supports optimal outcomes for these rare but highly actionable molecular alterations.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.